Terns Pharmaceuticals

Biotechnology Research51-200 employeesPublic CompanyFounded 2017

Reimagining known biology to deliver high impact medicines

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Specialties

PharmaceuticalsLiver DiseaseLife SciencesBioPharmaceuticalsCMLOncologyHemOnc

Funding

Public

US$ 150.2Mlast round, Oct 20246 total rounds

0 open remote positions

No matching jobs found

Try adjusting your search criteria or filters to find what you're looking for.